Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: First Intervention (14 days) Clear all
Completed Phase 3 Interventional

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00006363
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
cytarabine, daunorubicin hydrochloride, etoposide, valspodar, filgrastim, busulfan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, aldesleukin, clinical observation, pharmacological study
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 59 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Fuel and Rhythm (FAR) Phase 2 Study

NCT05482711
View directory record Official record
Conditions
Aging
Interventions
Time Restricted Eating Intervention
Other
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Terminated Not applicable Interventional

Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery

NCT03706963
View directory record Official record
Conditions
Abdominal Surgery
Interventions
Phone Call
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 10, 2026, 4:49 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Financial Incentives for Increasing Exercise

NCT01043757
View directory record Official record
Conditions
Sedentary Lifestyle, Obesity
Interventions
Financial incentives for increasing physical exercise
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 10, 2026, 4:49 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

NCT05172258
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Lancaster, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Normative Database and Test-Retest Reliability for BrainCheck Assessments

NCT05497427
View directory record Official record
Conditions
Cognitive Change, Cognitive Decline, Cognitive Deterioration, Neurocognitive Deficit
Interventions
BrainCheck Assessment
Device
Lead sponsor
BrainCheck, Inc.
Other
Eligibility
50 Years and older
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
5
States / cities
Palo Alto, California • Multiple Locations, Connecticut • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

NCT01347034
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
External Beam Radiation Therapy (RT), Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dyadic, Skills-Based Primary Prevention for Partner Violence in Perinatal Parents

NCT02009111
View directory record Official record
Conditions
Intimate Partner Violence
Interventions
Couple CARE for Parents
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Not applicable Interventional

TARA Working Prototype Engagement Evaluation: Feasibility Study

NCT04085302
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Digital Behaviour Change Intervention
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Not applicable Interventional

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

NCT01505569
View directory record Official record
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 4 Interventional

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

NCT06887959
View directory record Official record
Conditions
Acute Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Sarasota, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

NCT00777491
View directory record Official record
Conditions
Bladder Cancer
Interventions
induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 10, 2026, 4:49 PM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Not applicable Interventional

Active Injury Management (AIM) After Pediatric Concussion

NCT03869970
View directory record Official record
Conditions
Brain Concussion
Interventions
REST, ACTIVITY, mHEALTH
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
11 Years to 24 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 10, 2026, 4:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Paul Richardson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

NCT05413304
View directory record Official record
Conditions
Glioma
Interventions
Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra, abemaciclib + temozolomide, Temozolomide, Brain MRI, Brain CT, EKG, Chest X-ray, Biopsy/resection
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Ozurdex for the Control of Uveitis

NCT02049476
View directory record Official record
Conditions
Uveitis, Intermediate, Uveitis, Posterior
Interventions
Dexamethasone pellet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 10, 2026, 4:49 PM EDT
Recruiting No phase listed Observational

A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

NCT05789758
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
No Intervention
Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 54 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

NCT02824055
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 10, 2026, 4:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Middle School Science Teachers to Address Cancer Health Disparities

NCT07501689
View directory record Official record
Conditions
Cancer Risk Factors, Cancer Prevention
Interventions
CARES4You Curriculum
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
10 Years and older
Enrollment
1,812 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
5
States / cities
Brooklyn, New York • New York, New York • Queens, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 10, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

NCT00597402
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Brain Tumor
Interventions
Avastin, Temozolomide, Radiation Therapy (XRT), Irinotecan
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 10, 2026, 4:49 PM EDT
Terminated No phase listed Observational

An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate

NCT02520557
View directory record Official record
Conditions
SCAR
Interventions
Blood or Saliva
Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Not listed
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 10, 2026, 4:49 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

NCT01482286
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 10, 2026, 4:49 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

SHARE Program: SUSTAIN

NCT06934395
View directory record Official record
Conditions
Hiv
Interventions
Healthy Choices, Text Message Prompts
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 29 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Tallahassee, Florida • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 4:49 PM EDT